Skip to main content

Chevallard Daniel R.'s Form 4 filing

Viracta Therapeutics, Inc.VIRX · filed May 26, 2023

Accession no.
0001209191-23-032707
Filed
May 26, 2023
Trade date
May 25, 2023
Filing delay
1 day
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $5.16K. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Chevallard Daniel R.CIK 0001706176Officer (CFO and COO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 25, 2023Common StockMOption exerciseAcquired+6,889$0.00F1$095,912Direct
May 25, 2023Common StockSSaleDisposed−3,635$1.42F3−$5,161.792,277Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 25, 2023Common StockMOption exerciseDisposed−6,889$0.00$055,110Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each restricted stock unit ("RSU") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock.

Referenced by the price of 1 transaction in Table I.

F3

Represents the weighted average share price of an aggregate total of 3,635 shares sold in the price range of $1.41 to $1.42 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)